Please wait while the formulary information is being retrieved.
NEXVIAZYME (avalglucosidase alfa-ngpt)
- Pompe disease
100 mg intravenous solution
- Infuse 20 mg/kg by intravenous route every 2 weeks at a rate of 1 mg/kg/hr for 30 minutes may increase up to a max rate of 7 mg/kg/hr
Default screening record
- Infuse 20 mg/kg by intravenous route every 2 weeks at a rate of 1 mg/kg/hr for 30 minutes may increase up to a max rate of 7 mg/kg/hr
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Chronic heart failure
NEXVIAZYME (avalglucosidase alfa-ngpt)
- Pompe disease
- Hypersensitivity drug reaction
- Arthralgia
- Dizziness
- Fatigue
- Headache disorder
- Myalgia
- Paresthesia
- Urticaria
More Frequent
Severe
Less Severe
- Acute respiratory distress syndrome
- Anaphylaxis
- Hypertension
- Hypotension
- Acute abdominal pain
- Chest discomfort
- Chills
- Cough
- Dysphagia
- Dyspnea
- Erythema
- Nausea
- Ocular redness
- Pruritus of skin
- Skin rash
- Upper abdominal pain
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Tongue swelling
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Avalglucosidase alfa-ngpt
Safety and effectiveness not established in pediatric patients < 1 year.
- 1 Day – 364 Days
- Safety and effectiveness not established in pediatric patients < 1 year.
Avalglucosidase Alfa-ngpt
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Avalglucosidase Alfa-ngpt
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Avalglucosidase alfa may cause certain serious side effects, including allergic and infusion reactions. To decrease your risk of infusion reactions, you may be given other medications before each dose (such as antihistamines, corticosteroids). A health care professional will also carefully monitor you during your infusion.<br /><br />Get medical help right away if you notice any signs of a serious allergic or infusion reaction, such as flushing/rash, itching/swelling (especially of the face, tongue, throat), severe dizziness, trouble breathing, trouble swallowing, cough, or chest discomfort/tightness. Your infusion may be slowed down or stopped depending on your symptoms. Before starting treatment with this medication, tell your doctor if you have a history of heart problems (such as heart failure), breathing problems (such as fluid in the lungs), or swelling.<br /><br />These problems may get worse during the infusion. Your doctor may check your blood pressure, pulse (heart rate), and breathing more often during your infusion.
| Lysosomal alpha-1,4-glucosidase deficiency | |
| E74.02 | Pompe disease |
| 0-9 | A-Z |
|---|---|
| E74.02 | Pompe disease |
Formulary Reference Tool